One of the phenotypic hallmarks of high CD133-expressing tumors is the ability to grow as patient-derived xenografts in immunocompromised mice—an ability that IDHmut gliomas, but not other IDHmut cancers, typically lack6. This evidence concerns the gene PROM1 and cancer.